Cemiplimab's proposed EU regimen could cut Libtayo infusion visits from every 3 weeks to every 6 weeks, trimming infusion time by up to half.
|Articles|March 11, 2022
Life Science Executives Issue Call to Cut Business Ties with Russia
Author(s)BioPharm International Editors
Various executives in the life sciences industry have started a petition calling for “complete economic disengagement” with Russia.
Advertisement
Various life sciences executives, including representatives from Ovid Therapeutics, Nkarta Therapeutics, and Alnylam Therapeutics, released a paper calling for fellow businesses to cease all business involvement with Russia. Until such a time that “restoration of peace and democracy [is achieved] in a sovereign Ukraine,” the authors ask that fellow businesses:
- Cease investment in Russian companies
- Reject Russian investments
- Halt collaboration or service agreements with Russian companies
- Halt trade in goods and services with Russian companies (except for food and medicines).
“We cannot look back in the future wondering whether we could have taken stronger measures.” reads the statement. “This justifies the strongest possible economic disengagement now.”
Advertisement
Related to this article
Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains where cold-chain planning still breaks down and why biopharma supply chain leaders should use AI to act on data sooner, with humans making the final call.
The FDA grants accelerated approval to Ultomiris for IgA nephropathy, Alcon acquires Neurotech and its MacTel cell therapy for $550 million, and BioNTech and Bristol Myers Squibb add Trodelvy to a phase 3 trial in triple-negative breast cancer.
Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.
Revakinagene taroretcel (Encelto), the only FDA-approved MacTel therapy, slowed photoreceptor loss by up to 54.8% vs sham in phase 3 trials.
BioNTech and Bristol Myers Squibb will replace chemotherapy with Gilead’s TROP2-directed ADC sacituzumab govitecan in the Phase 3 ROSETTA Breast-01 trial of PD-L1×VEGF-A bispecific pumitamig in PD-L1-low or -negative TNBC.
Alexion’s ravulizumab won accelerated approval to reduce proteinuria in adults with IgA nephropathy after the Phase 3 I CAN trial showed a 43.4% placebo-adjusted reduction at Week 34.
Sanofi breaks ground on an EU-backed insulin API plant in Frankfurt, Summit and ECOG-ACRIN launch a phase 2/3 trial of ivonescimab in first-line biliary tract cancer, and TaiMed’s anti-CD4 antibody TMB-365 lowers HIV viral load in phase 1.
Advertisement
Advertisement
Trending on BioPharm International
1
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
2
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
3
FDA Grants Accelerated Approval to Ultomiris as First C5 Inhibitor for IgA Nephropathy
4
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
5